Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Sell
25
SCPH Quote, Financials, Valuation and Earnings
Last price:
$2.27
Seasonality move
:
-3.25%
Day range:
$2.47 - $2.64
52-week range:
$1.94 - $5.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.04x
P/B ratio:
9.36x
Volume:
81.9K
Avg. volume:
397.8K
1-year change:
-46.78%
Market cap:
$124.7M
Revenue:
$36.3M
EPS (TTM):
-$1.90
Analysts' Opinion
-
Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.17, scPharmaceuticals has an estimated upside of 511.56% from its current price of $2.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $2.48.
Fair Value
-
According to the consensus of 4 analysts, scPharmaceuticals has 511.56% upside to fair value with a price target of $15.17 per share.
SCPH vs. S&P 500
-
Over the past 5 trading days, scPharmaceuticals has underperformed the S&P 500 by -0.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
scPharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
scPharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter scPharmaceuticals reported revenues of $12.2M.
Earnings Growth
-
scPharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter scPharmaceuticals reported earnings per share of -$0.35.
Enterprise value:
100.4M
EV / Invested capital:
--
Price / LTM sales:
3.04x
EV / EBIT:
--
EV / Revenue:
2.76x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-1.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$25M
Return On Assets:
-90.4%
Net Income Margin (TTM):
-234.36%
Return On Equity:
-370.01%
Return On Invested Capital:
-126.82%
Operating Margin:
-134.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $13.6M | $36.3M | $6.1M | $12.2M | |
| Gross Profit | -- | $9.8M | $25M | $4.3M | $8.2M | |
| Operating Income | -$36.2M | -$55.4M | -$64.8M | -$15.3M | -$16.3M | |
| EBITDA | -$33.1M | -$46.5M | -$77.5M | -$11.7M | -$17.4M | |
| Diluted EPS | -$1.30 | -$1.42 | -$1.90 | -$0.35 | -$0.35 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $107.8M | $78.3M | $123.3M | $92.9M | $105.8M | |
| Total Assets | $109M | $79M | $124.2M | $94.5M | $107.5M | |
| Current Liabilities | $9.3M | $14.8M | $7.4M | $13.1M | $14.9M | |
| Total Liabilities | $26.9M | $22.6M | $51.8M | $57.3M | $94.2M | |
| Total Equity | $82.2M | $56.5M | $72.4M | $37.2M | $13.3M | |
| Total Debt | -- | -- | -- | $38.8M | $51.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.6M | -$59.2M | -$70.5M | -$15.2M | -$15.2M | |
| Cash From Investing | -$45.9M | $20M | $29.3M | $26.5M | -$12K | |
| Cash From Financing | $77.2M | $14.9M | $70.1M | $467K | -$631K | |
| Free Cash Flow | -$34.6M | -$59.3M | -$70.6M | -$15.2M | -$15.2M | |
SCPH
Sector
Market Cap
$124.7M
$35.1M
Price % of 52-Week High
43.89%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
-31.67%
-0.74%
1-Year Price Total Return
-46.78%
-40.62%
Beta (5-Year)
0.170
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.50
200-day SMA
Sell
Level
$3.80
Bollinger Bands (100)
Sell
Level
2.68 - 3.5
Chaikin Money Flow
Sell
Level
-16.4M
20-day SMA
Buy
Level
$2.46
Relative Strength Index (RSI14)
Sell
Level
45.86
ADX Line
Buy
Level
11.19
Williams %R
Neutral
Level
-53.8462
50-day SMA
Sell
Level
$2.78
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-27.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.6703)
Sell
CA Score
(Annual)
Level (-4.9339)
Sell
Beneish M-Score
(Annual)
Level (-0.4982)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.1058)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Stock Forecast FAQ
In the current month, SCPH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SCPH average analyst price target in the past 3 months is $15.17.
-
Where Will scPharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that scPharmaceuticals share price will rise to $15.17 per share over the next 12 months.
-
What Do Analysts Say About scPharmaceuticals?
Analysts are divided on their view about scPharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that scPharmaceuticals is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is scPharmaceuticals's Price Target?
The price target for scPharmaceuticals over the next 1-year time period is forecast to be $15.17 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SCPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for scPharmaceuticals is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SCPH?
You can purchase shares of scPharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase scPharmaceuticals shares.
-
What Is The scPharmaceuticals Share Price Today?
scPharmaceuticals was last trading at $2.27 per share. This represents the most recent stock quote for scPharmaceuticals. Yesterday, scPharmaceuticals closed at $2.48 per share.
-
How To Buy scPharmaceuticals Stock Online?
In order to purchase scPharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
